A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

NCT03347422 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Cold Agglutinin Disease

Interventions

DRUG: sutimlimab (BIVV009)
DRUG: placebo

Sponsor

Bioverativ, a Sanofi company